DOCSLIB.ORG

Burnet Annual Report 2020

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

Burnet Institute Annual Report 2020 A year of challenges during a global pandemic ANNUAL REPORT 2020 > 3 Burnet Institute is an Australian, unaligned, independent, not-for-pro t organisation that aims to achieve better health for vulnerable communities globally. CONTENTS About Burnet Community and Education 01 Our Vision, Mission and Global Impact 22 Studying during COVID-19 02 Our Leadership Team 23 Key Publications 02 Chairman’s Message 24 Thanks to our Supporters 03 Director’s Message 25 In Appreciation 04 Program-led Institute 05 Congratulations to Awardees Annual Financial Report 06 2020 At A Glance 26 Financial Summary 27 Consolidated Statement of Our Research Impact Profit or Loss and Other 10 COVID-19: How Science Matters Comprehensive Income 12 COVID-19: Know-C19 Hub 28 Consolidated Statement of 13 COVID-19: Masks - Evidence-based Financial Position Advocacy 29 Burnet Institute International 14 COVID-19: Optimise Development Activities 15 COVID-19: The Power of Modelling Operating Statement 16 Boosting COVID-19 Awareness 30 Independent Auditor’s Report in Papua New Guinea 17 Innovation: In the Pipeline 18 Changing Lives 20 Translating our Research OUR VISION Equity through better health OUR MISSION OUR GLOBAL IMPACT To achieve better Our priority countries are: health for vulnerable • AUSTRALIA communities in Australia • PAPUA NEW GUINEA • MYANMAR and internationally by accelerating the We support research and public health programs in other countries in the translation of research, Asia-Paci c Region and Africa including discovery and evidence Cambodia, China, India, Indonesia, Kenya, Lao People’s Democratic Republic, Malawi, into sustainable Paci c Islands, South Africa, Thailand, health solutions. Timor-Leste, Vietnam and Zimbabwe. ANNUAL REPORT 2020 > 1 Our Leadership Team CHAIRMAN’S MESSAGE Preparation of the Institute’s new strategic plan is well underway. While the vision The past year has been extremely and purpose of the Institute will not alter, challenging. The onset of the COVID-19 additional activities that strengthen our pandemic has emphasised the critical indigenous health programs and health importance of medical research and the issues associated with a rapidly changing role Burnet can play. While we had to world will be incorporated. In addition, the reduce research activity in some areas, newly announced Australian Institutes of especially our international work, we Infectious Diseases and Global Health and were able to pivot to focus our eorts on the proposed relocation of Burnet to the the response to COVID-19. Parkville Precinct, will play a large part in Our scientists have been heavily the Institute’s long-term development and involved in laboratory-based vaccine strategic collaborations. and rapid diagnostics research, as well The sale of Burnet’s ‘real estate‘ assets at as the public health response through Commercial Road in 2020 helped place Ms Mary Padbury modelling and research focused on the Institute in its strongest ever nancial CHAIRMAN the prevention of new infections, position. This position should be rther and reducing the health, societal BA, LLB(Hons) enhanced with the proposed sale of the Chairman of Burnet Institute and economic impacts of COVID-19 Institute’s shareholding in 360biolabs, from 2019. Director since 2011. restrictions. In addition, a number of sta Chair, Clinical Genomics enabling the Institute to focus on were extremely active in advisory roles, Technologies Pty Ltd. advancing a number of new initiatives. Non-Executive Director, in advocacy and communications, and Commonwealth Bank of Australia. in supporting the Federal and Victorian A special thank you to my fellow board Former Chair, Trans-Tasman IP Departments of Health. members and to our wonderl Director Attorneys Board. Former Chairman and CEO, Professor Brendan Crabb AC and of Blake Dawson/Ashurst Australia and Vice Chairman of Ashurst LLP. his talented and hard-working executive I have been extremely proud of team for their outstanding leadership >>> all our people. Their resilience during this period. and ability to adapt to changing I would also like to thank our many circumstances and make a supporters who extended their giving to very positive contribution has nd many of Burnet’s COVID-19 programs, been inspiring. as well as continuing to support our ongoing work. Your support is essential and greatly valued and appreciated by all at Burnet. DIRECTORS The richness and diversity of expertise and skills amongst our Board and Executive leadership team is matched by their dedication and commitment to lead Burnet’s mission. Our Board’s expertise spans medical research, public health, medicine, law, business development, advocacy, communications, nance, corporate governance and innovation. Mr Robin Professor Professor Associate Professor Mr Benjamin Bishop Peter Colman AC Sandra Eades Helen Evans AO Foskett LLB(Hons), BCom, BA PhD, FRS, FAA, FTSE BMed, PhD BA, BSocAdmin BBus(Acc), FAICD ANNUAL REPORT 2020 > 2 DIRECTOR’S MESSAGE In PNG, the health system is under signi cant pressure with increasing COVID-19 From an Institute perspective, 2020 cases, and resources have been redirected will be remembered as one of the most to support the national and provincial health challenging in our history, but also one authorities. The situation in Myanmar is of our most successl. The onset of the very concerning, and where possible, we COVID-19 pandemic required a complete continue to maintain contact and provide reassessment of the Institute’s priorities support to our sta. and operations, to maximise our contribution to the local, national and Despite the challenges, the Institute international response, and ensure the continued to perform exceptionally well safety and wellbeing of our sta. against key indicators. Competitive grants and peer-reviewed publications were at record levels, and our national and Our focus on mathematical international collaborations strengthened. >>> modelling, public health responses, We continue to grow our operations, while at behavioural science, vaccines the same time, create an improved nancial Professor and rapid diagnostics delivered base. The Institute was also awarded an Brendan Crabb AC enormous value for the country Athena SWAN Institutional Bronze Award DIRECTOR AND CHIEF and the region. from Science in Gender Equity (SAGE), EXECUTIVE OFFICER acknowledging the signi cant commitment and work undertaken to address gender PhD, FAHMS Information sharing through our purpose- Director and CEO of Burnet equity including diversity and inclusion. Institute since 2008. built Know-C19 Knowledge Hub initiative, I am very gratel to all the Burnet sta Chair of the Paci c Friends and extensive private and public advocacy, of Global Health, Chair of for their incredible commitment and provided up-to-date and timely information VicAAMRI, Member of National contributions to the Institute, especially for everyone – governments and public Health and Medical Research in such trying times. Many have worked Council (NHMRC) of Australia, – and contributed signi cantly to the extremely long hours in making a huge impact Member of the National amazing ‘COVID-zero’ outcome for Australia. to the national and international response COVID-19 Health and Research The centrepiece was beating the Victorian Advisory Committee (NCHRAC). to the pandemic. My thanks to the Board, second wave in a complete way not seen in especially to our Chairman, Mary Padbury any other jurisdiction in the world. who works riously and expertly for our Our international operations in Papua New bene t, and to our brilliant Executive. And Guinea (PNG) and Myanmar have been nally, a special acknowledgement of the signi cantly impacted by the pandemic, Coronavirus Management Team who were but more recently, sadly complicated by the crucial in steering the Institute through this political unrest in Myanmar. most challenging time. Mr John Mr Leigh Ms Alison Professor Georgakis Jasper Larsson Sharon Lewin AO BBus(Acc) BE(Hons), BSc BEc, CPA, GAICD MBBS(Hons), PhD, FRACP Professor Christina Ms Miche Dr Serge Scrofani Mr Michael Mitchell AO Paterson BSc(Hons), PhD, Ziegelaar MBBS, PhD, FRACP MBA, GAICD LLB(Hons), BEc, LLM ANNUAL REPORT 2020 > 3 Program-ledPROGRAMLED INSTITUTE Institute Institute-wide interdisciplinary health programs are at the heart of our daily decision-making. 470 26 SCIENTISTS, WORKING Each thematic program represents the breadth PUBLIC HEALTH GROUPS of our technical skill base that fosters a PROFESSIONALS collaborative approach to tackle some of the AND SUPPORT STAFF most challenging global health issues. BURNET ¡ A FOUNDATION PARTNER IN AN INFECTIOUS DISEASE GLOBAL HEALTH HUB 4 THEMATIC PROGRAMS Burnet Institute welcomed the DISEASE ELIMINATION Victorian Government’s nding Program Goal: to create the Australian Institutes To eliminate disease to of Infectious Diseases and Global achieve good health for all Health (AIIDGH) that will signi cantly enhance the capacity to respond to throughout life critical global health issues such as pandemics. The AIIDGH will maximise the MATERNAL, CHILD AND strengths of Burnet Institute, ADOLESCENT HEALTH Doherty Institute and the University Program Goal: of Melbourne, and scale up preparedness for infectious diseases Equity in maternal, child and of national and global signi cance. adolescent health It will also address the gaps identi ed in the COVID-19 response. The nding of $150 million BEHAVIOURS AND announced by the Premier of HEALTH RISKS Victoria, the Hon Daniel Andrews
Recommended publications
  • Download the Burnet/360Biolabs Media Release

    Download the Burnet/360Biolabs Media Release

    MEDIA RELEASE 16 August 2021 Transformational day for Burnet with the sale of 360biolabs Melbourne, Victoria: The Burnet Institute majority owned company 360biolabs has signed an agreement to be purchased by BioAgilytix Labs, LLC (BioAgilytix), a leading global contract research laboratory focused on large molecule drug development and bioanalysis. Headquartered in North Carolina, USA, BioAgilytix Labs also has laboratories in Boston, and Hamburg, Germany. While the precise purchase price remains commercial-in-confidence, the sale will mean several hundred million dollars in revenue for Burnet, more than tripling our current corpus. The acquisition is subject to Australian Foreign Investment Review Board (“FIRB”) requirements and is expected to be complete in the third quarter of 2021. Burnet Institute Director and CEO, Professor Brendan Crabb AC said it was a transformational achievement for the Institute and welcomed the visionary strategic focus of BioAgilytix to build on 360biolabs’ world-class virology and immunology expertise. “Burnet Institute is proud of its involvement in the foundation of 360biolabs. It is the right time, with the growing need for high quality clinical trial support, for a company of the scale, capability, and reputation of 360biolabs to join with BioAgilytix and expand their capacity to service their customers and facilitate high quality translational medical research,” Professor Crabb said. With science playing such a leading role in the COVID-19 global pandemic response, Professor Crabb said the sale was another remarkable success story, not only for the Institute and the 360biolabs team, but also for showcasing the importance of ongoing support by Victorian and Federal governments in investing heavily in the world renown medical research sector in Melbourne and throughout Australia.
  • Menzies School of Health Research

    Menzies School of Health Research

    MENZIES SCHOOL OF HEALTH RESEARCH 2020-21 Pre-Budget Submission September 2020 Contact: Professor Alan Cass Director, Menzies School of Health Research Ph: 08 8946 8600 Email: [email protected] Web: www.menzies.edu.au ABN: 70 413 542 847 Menzies School of Health Research (Menzies) is pleased to put forward its 2020-21 Pre-Budget submission. 1. Summary of recommendations The medical and health research sector has an important role in supporting economic growth, job creation and attracting investment to Australia. This role has been further emphasised in key policy statements from both the Northern Territory and Commonwealth Governments to ensure the future prosperity of northern Australia. For example, medical and health research is a stated economic priority in the Northern Territory Economic Development Framework and its Economic Reconstruction Priorities, as well as being highlighted as a strategic priority in the Commonwealth’s White Paper on Developing Northern Australia. Directly related to supporting medical and health research in northern Australia, this pre-budget submission requests that the Commonwealth provide $5m to support a four (4) year extension to the Northern Australia Tropical Disease Collaborative Research Program (NATDCRP), administered by Menzies School of Health Research in collaboration with seven (7) of Australia’s leading health research organisations – James Cook University, Telethon Kids Institute, Burnet Institute, The University of Sydney, the South Australian Health and Medical Research Institute, Doherty Institute and QIMR Berghofer Medical Research Institute. The NATDCRP – now referred to as the HOT North Program - was announced as a $6.8m budget measure by the Minister for Trade and Investment, the Hon Andrew Robb on 10 May 2015.
  • Annual Report | 2015

    Annual Report | 2015

    Annual Report 2015 Celebrating years 15 years of influence Mc Keon MRFF MRFF Research Wills Review Beyond Grant Review Global Threat of 10 Strategic Review created to Beyond proposed Australia funding Discovery Funding Financial $400m Imperatives recommends deliver extra Discovery II in Federal established doubles launched Doubles Crisis funding cut launched more research $1 billion Budget funding funding 900 NMHRC Annual Expenditure 2000 – 2015 800 Millions ($) 700 600 500 400 300 Howard Rudd – Gillard – Rudd Abbott – Turnbull 200 Government Government Government 100 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 Research Australia Leadership Chair: Peter Wills Chair: Prof John Niland Chair: Chris Roberts CEO: Rebecca James Chair: Prof CEO: Elizabeth Vice Chancellor of UNSW Christine Foley CEO: Bev Dyke Bennett CEO: Dr Christine Bennett *Dr Jane Glatz was acting CEO part of 2002 Published November 2015 2 Chairman’s Foreword A reflection on 15 years Fifteen years ago, Peter Wills AC in his landmark report1 Research Australia has always valued the role a well-informed recommended the establishment of Research Australia – an and engaged community has in highlighting research as a alliance for discoveries in health to the then Prime Minister, priority for government and health. Campaigns such as ‘Thank John Howard, OM, AC and Health Minister, Dr Michael You Day’, ‘Cook For A Cure’ and, of course, our Research Australia Wooldridge. Based on Research!America the establishment Annual Awards Night have been powerful opportunities for of this new organisation brought together all aspects of “the telling the stories behind the great research and innovation.
  • Melbourne Biomedical Precinct Studley Rd to an Exceptional Network Economic and Investment Growth Swinburne University of of Skilled Workers, Quality for the State

    Melbourne Biomedical Precinct Studley Rd to an Exceptional Network Economic and Investment Growth Swinburne University of of Skilled Workers, Quality for the State

    The Royal Children’s Hospital + The Murdoch Children’s Research Institute The Royal Women’s Hospital Darwin Walter & Eliza Hall Institute Monash Institute of Pharmaceutical NT Science, Monash University + CSIRO QLD Royal Melbourne Hospital WA Brisbane C Florey Institute SA e m ete ry Rd The University of Melbourne NSW Perth Sydney A Precinct approach Victorian Comprehensive Cancer Centre Adelaide Royal Pde Canberra + Peter MacCallum Cancer Centre The Doherty Institute to collaboration Flemington Rd Elgin St St Vincent’s Hospital Melbourne Hobart Melbourne, Grattan St Swanston St Australia and innovation Arden St Curzon St Elizabeth St Lygon St La Trobe University Queensberry St d R g r e b Burgundy St Rathdowne St l Chetwynd St Victoria St e > id e Melbourne Brain Centre H r Peel St e Austin Health p Plan Melbourne, Victoria’s key metropolitan Franklin St p Melbourne has biomedical La Trobe St U Austin Hospital planning strategy, highlights the precincts Banksia St capabilities unparalleled in around Melbourne, Monash, Deakin, Olivia Newton-John Australia and amongst the and La Trobe universities as clusters CSL Cancer Wellness & world’s best. We are home which offer significant opportunities (Poplar Road) Research Centre for innovation as well as employment, Melbourne Biomedical Precinct Studley Rd to an exceptional network economic and investment growth Swinburne University of of skilled workers, quality for the state. Technology education providers, leading The Melbourne Biomedical Precinct Deakin University St Kilda Rd research institutes and a Partners are largely collocated to the Princes Hwy Commercial Rd Burwood & Geelong Campuses sophisticated health system. north of Melbourne’s CBD close to Monash University, Australia’s highest ranking university, Clayton � Caulfield There is a growing body of evidence the University of Melbourne.
  • 2010-2011 Annual Report

    2010-2011 Annual Report

    Annual Report 2010-2011 Mastery of disease through discovery | www.wehi.edu.au Contents 1 About the institute 3 Director’s and Chairman’s report 5 Discovery 8 Cancer and Haematology 10 Stem Cells and Cancer 12 Molecular Genetics of Cancer 14 Chemical Biology 16 Molecular Medicine 18 Structural Biology 20 Bioinformatics 22 Infection and Immunity 24 Immunology The Walter and Eliza Hall Institute 26 Autoimmunity and Transplantation of Medical Research 28 Cell Signalling and Cell Death 1G Royal Parade 30 Inflammation Parkville Victoria 3052 Australia Telephone: (+61 3) 9345 2555 32 Molecular Immunology Facsimile: (+61 3) 9347 0852 34 Publications WEHI Biotechnology Centre 36 Awards 4 Research Avenue 37 Translation La Trobe R&D Park Bundoora Victoria 3086 Australia Translating our research 38 Telephone: (+61 3) 9345 2200 40 Developing our research Facsimile: (+61 3) 9345 2211 42 Patents www.wehi.edu.au www.facebook.com/WEHIresearch 43 Education www.twitter.com/WEHI_research 46 2010-11 graduates ABN 12 004 251 423 47 Seminars Acknowledgements 48 Institute awards Produced by the institute’s Community Relations department 49 Engagement Managing editor: Penny Fannin Editor: Liz Williams 51 Strategic partners Writers: Liz Williams, Vanessa Solomon and Julie Tester 52 Scientific and medical community Design and production: Simon Taplin Photography: Czesia Markiewicz and Cameron Wells 54 Public engagement 57 Engagement with schools Cover image 58 Donor and bequestor engagement Art in Science finalist 2010 Vessel webs 59 Sustainability Dr Leigh Coultas, Cancer and Haematology division 60 The Board This image shows the delicate intricacy in the developing eye of a transient population of web-like blood vessels.
  • Survey of Commercial Outcomes from Public Research (Scopr) 2019 Report

    Survey of Commercial Outcomes from Public Research (Scopr) 2019 Report

    techtransfer.org.au SURVEY OF COMMERCIAL OUTCOMES FROM PUBLIC RESEARCH (SCOPR) 2019 REPORT Survey and report delivered by FOREWORD There is an ever-present imperative to capture the commercial value of our research endeavour for our future wellbeing. To do so strategically, decision makers from laboratory, institutional and government levels need insights into how the research sector is currently engaging with industry to transfer knowledge and innovation, and thereby deliver benefits to our society from the fruits of our research. For many years in Australia there has been a focus on improving innovation metrics, thus I am delighted to acknowledge the initiative of gemaker and Knowledge Commercialisation Australasia (KCA) in producing the inaugural Survey of Commercial Outcomes from Public Research (SCOPR). The SCOPR takes its lead from the National Survey of Research Commercialisation (NSRC) produced since 2000 by the Department of Industry, Science, Energy and Resources. To avoid duplication, the Department has decided to cease the NSRC and will work with KCA to share knowledge, and access data collected by SCOPR. As we face the COVID-19 pandemic, effective knowledge transfer is more important than ever, so I hope that this report will spur our research institutions to even greater achievements. Realising effective knowledge transfer will depend on having skilled commercialisation professionals who can help researchers turn great ideas into beneficial products and services. I applaud KCA’s support for technology transfer professionals
  • 2.6 Oceania 145 2.6 OCEANIA

    2.6 Oceania 145 2.6 OCEANIA

    Regional Overview 2.6 Oceania 145 2.6 OCEANIA AUSTRALIA FIJI KIRIBATI MARSHALL ISLANDS MICRONESIA, FEDERATED STATES OF NAURU NEW ZEALAND PALAU PAPUA NEW GUINEA SAMOA SOLOMON ISLANDS TIMOR LESTE TONGA TUVALU VANUATU 146 Global State of Harm Reduction 2020 TABLE 2.6.1: Epidemiology of HIV and viral hepatitis, and harm reduction responses in Oceania Country/ People who HIV Hepatitis C Hepatitis B Harm reduction response territory with inject drugs prevalence (anti-HCV) (anti-HBsAg) reported among prevalence prevalence injecting drug people who among among 1 Peer use inject drugs people who people who 2 3 4 (%) inject drugs inject drugs NSP OAT distribution DCRs (%) (%) of naloxone (2,940)7 Australia 75,1785[2] 2.3[3] 45[4] 4.0[5] (4,182)6[2] [7,8] 2 (B,M)[6] Federated States nk nk nk nk x x x x of Micronesia Fiji nk nk nk nk x x x x Kiribati nk nk nk nk x x x x Marshall Islands nk nk nk nk x x x x New Zealand 18,0008[10] 0.2[10] 589[10] nk (185)10[11] (B,M)[11,12] 11[9] x Palau nk nk nk nk x x x x Papua New nk nk nk nk x x x x Guinea Samoa nk nk nk nk x x x x Solomon Islands nk nk nk nk x x x x Timor Leste nk nk nk nk x x x x Tonga nk nk nk nk x x x x Vanuatu nk nk nk nk x x x x nk = not known 1 Countries with reported injecting drug use according to Larney et al 2017.
  • Fellowship of the Australian Academy of Health and Medical Sciences January 2019

    Fellowship of the Australian Academy of Health and Medical Sciences January 2019

    FELLOWSHIP OF THE AUSTRALIAN ACADEMY OF HEALTH AND MEDICAL SCIENCES JANUARY 2019 Fellowship Year Name of Fellow Primary Position Primary Institution State Office Inducted Pro Vice Chancellor of Health and Medicine Professor John (Robert) Aitken Fellow 2015 The University of Newcastle NSW Laureate Professor of Biological Sciences Senior Staff Specialist The Children’s Hospital at Westmead Professor Ian Alexander Fellow 2015 NSW Head, Gene Therapy Research Unit Children’s Medical Research Institute Professor Warren Alexander Fellow 2015 Joint Head, Cancer and Haematology Division The Walter and Eliza Hall Institute of Medical Research VIC Professor Katie (Katrina) Allen Fellow 2015 Theme Director, Population Health Consultant Paediatrician Murdoch Children's Research Institute, The Royal Children’s Hospital VIC Professor Craig Anderson Fellow 2015 Senior Director, Neurological and Mental Health Division The George Institute for Global Health NSW Professor Vicki Anderson Fellow 2015 Head of Psychology, RCH Mental Health Royal Children’s Hospital VIC Professor Warwick Anderson Fellow 2015 Deputy Director, Centre for Values, Ethics and the Law in Medicine The University of Sydney NSW Professor Warwick Anderson AM Honorary Fellow 2015 Secretary General International Human Frontier Science Program Organization International Professor Ian Anderson AO Fellow 2018 Deputy Secretary, Department of Prime Minister & Cabinet Commonwealth Government of Australia ACT Professor James Angus AO Honorary Fellow 2015 Honorary Professorial Fellow and Emeritus
  • The Bio21 Institute's 2020 Annual Report Is Available to Download

    The Bio21 Institute's 2020 Annual Report Is Available to Download

    Annual Report 2020 Image of the coronavirus SARS-CoV-2 taken by Andrew Leis and Jason Roberts. Courtesy of the Doherty Institute. The Bio21 Molecular Science and Director Associate Director – Platform Biotechnology Institute Professor Michael W. Parker Infrastructure University of Melbourne DPhil (Oxon) FAA FAHMS Professor Malcolm McConville PhD 30 Flemington Road Deputy Director Associate Director – Commercialisation Parkville Victoria 3010 Professor Frances Separovic AO Professor Spencer Williams PhD Telephone: (03) 8344 2220 PhD FAA www.bio21.unimelb.edu.au Associate Director – Engagement @Bio21Institute Professor Sally Gras PhD @Bio21Institute Scientific Research Manager Dr David Keizer, PhD Produced by the Bio21 Molecular Science and Biotechnology External Relations Advisor,b Bio21 Florienne Institute Loder Annual Report 2020 Contents Our Mission 2 Our Vision 2 About the Institute 3 Director’s Message 4 Bio21 Leadership 8 Deputy Director, Professor Emeritus Frances Separovic AO 8 Associate Director Engagement – Professor Sally Gras 10 Associate Director Commercialisation – Professor Spencer Williams 13 Associate Director Platform Infrastructure – Professor Malcolm McConville 14 ACRF Facility for Innovative Cancer Drug Discovery 16 Impacts of Research 19 OHS Report 31 Equity Diversity and Inclusion 32 Industry Engagement and Commercialisation 35 Announcing the Ruth Bishop Building and Ian Holmes Imaging Centre 36 Events and Conferences 39 Graduate Research Students and Early Career Researchers 41 Institute Members Honoured 42 Grant Successes 43 Governance 46 Bio21 Scientific Research Team 47 Bio21 Research Groups 48 Bio21 People 50 Institute in Numbers 56 Bio21 Institute Theses submitted in 2020 57 Bio21 Steering Committee 58 Industry partners 63 Produced by the Bio21 Molecular Science aFontn Front cover image: Bio21 precinct aerial photograph, courtesy of Kane Jarrod Photography.
  • 2Nd Postdoc Methods Symposium Program

    2Nd Postdoc Methods Symposium Program

    Program Thursday, 13th September Event Approximate Time Location Registration Opens 8:30 – 9:00 Tapestry Lounge (in front of the Davis Auditorium) Session 1 9:00 – 10:20 Davis Auditorium 9:00 – 9:05 Organising Committee Welcome and Introductions 9:05 – 9:20 Daniel Brown An overview of single-cell omics methods, from Walter and Eliza Hall Institute technology to applications 9:20 – 9:35 Belinda Phipson Kidneys in a dish: examining the reproducibility Murdoch Children’s Research Institute of organoid differentiation using transcriptomics 9:35 – 9:50 Joanna Sacharz SELEX: In search of solubilizing nucleic acids Bio21 Institute, University of Melbourne KEYNOTE: A primer on single cell RNA-seq analysis 9:50 – 10:20 Matthew Richie Walter and Eliza Hall Institute Morning Tea 10:20 – 11:00 Tapestry Lounge posters & sponsor exhibits 2nd Postdoctoral Methods Symposium 2018 #PDMS2018 Event Approximate Time Location Session 2 11:00 – 12:15 Davis Auditorium MCFP sponsored talk Biological Imaging via Helium ion Microscopy 11:00 – 11:15 Babak Nasr University of Melbourne 11:15 – 11:30 Mohamed Fareh Single-molecule fluorescence reveals the Peter MacCallum Cancer Centre dynamics of microRNA recognition by Dicer- TRBP complex 11:30 – 11:45 Charis Teh Capturing the cellular gymnastics of survival Walter and Eliza Hall institute and killer proteins by mass cytometry (CyTOF) 11:45 – 12:00 Jieqiong Lou Phasor analysis and image correlation Bio21 Institute, University of Melbourne spectroscopy of histone FLIM/FRET reveals spatiotemporal regulation of chromatin organization by the DNA damage response. Session 2 Flash talks 12:00 – 12:15 Davis Auditorium Rachel Lundie Flow FISH as a method to elucidate the Walter and Eliza Hall Institute transcriptional effects of M.
  • Drug Discovery and Technology Capabilities at WEHI Melbourne, Australia History of WEHI

    Drug Discovery and Technology Capabilities at WEHI Melbourne, Australia History of WEHI

    Drug Discovery and Technology Capabilities at WEHI Melbourne, Australia History of WEHI • Established 1915 • Focused on the fundamental principles of medical biology to mitigate disease • Independent Research Institute affiliated with University of Melbourne, Royal Melbourne Hospital and the Victorian Comprehensive Cancer Center WEHI Overview 90 laboratories working on 120 Clinical trials 50+ diseases currently underway > +30 million patients world wide have 1200+ researchers benefited from our research and staff World-Class Research Across a Broad Range of Therapeutic Areas • WEHI performs influential basic and translational research focused on four key therapeutic areas: – Cancer – Immunology & Inflammation – Infectious diseases – Ageing and development Font size proportional to research effort per topic Fulfilling Our Mission • WEHI was ranked 19th in the 2019 Nature Index for global not-for-profit/non-governmental organizations. • Translating discoveries: Venetoclax = New targeted treatment for Chronic Lymphocytic Leukaemia approved by FDA in 2016. • Gender Equity in Research: WEHI is recipient of SAGE Athena SWAN Award + membership of Male Champions of Change. • Increased funding partnership with State government ➣ State government invests $18M in WEHI National Drug Discovery Centre (in addition to contributions announced by Federal government). History of our Drug Discovery Centre • First academic drug discovery infrastructure at an Australian research institute – High-throughput screening facility – Medicinal chemistry laboratories
  • Manual for Reducing Drug Related Harm in Asia the Centre for Harm Reduction, Macfarlane Burnet Centre for Medical Research and Asian Harm Reduction Network

    Manual for Reducing Drug Related Harm in Asia the Centre for Harm Reduction, Macfarlane Burnet Centre for Medical Research and Asian Harm Reduction Network

    Manual for REdrugDU relatedCI harmNG in Asia The Centre for Harm Reduction, Macfarlane Burnet Centre for Medical Research and Asian Harm Reduction Network Revised and Updated Manual for reducing drug related harm in Asia The Centre for Harm Reduction, Macfarlane Burnet Centre for Medical Research and Asian Harm Reduction Network This publication was made possible through support provided by the Office of Strategic Planning, Operations, and Technical Support, Bureau for Asia and the Near East, U.S.Agency for International Development, under the terms of Award No. HRN-A-00-97-00017-00 to Family Health International.The opinions expressed herein are those of the author(s) and do not necessarily reflect the views of Family Health International or the U.S.Agency for International Development. The Manual for Reducing Drug-Related Acknowledgements Harm in Asia For contributions to chapters in section two: Sujata Rana (1), Dr Peter © Copyright The Centre for Harm Deutschmann (2), Paul Deany (3), Dave Reduction, 2003 Burrows (4). Thanks to the members of the Asian Harm Reduction Network Contact details (AHRN) particularly Palani Narayanan, The Centre for Harm Reduction Manisha Singh, Jimmy Dorabjee, Luke The Macfarlane Burnet Institute for Samson, Dr Salam Irene Singh, Ching Medical Research and Public Health Ltd Hangzo, Dr Chawalit Natpratan, Dr Commercial Road, Melbourne, Langkham, Dr Muana, Aaron Peak. Victoria, 3004, Australia Thanks also to Mangai Balasegaram, PO Box 2284, Melbourne, Odette Jereza, Don des Jarlais for Vic, 3001, Australia feedback on draft copies. Thanks to all Tel: +61 3 9282 2169 who responded to SEA-AIDS requests for Fax: +61 3 9482 3123 information especially Maria de Bruyn, E-mail: [email protected] John Strand and Ann Smith.